Breast cancer represents 15.2% of all new cancer cases and is the most frequently diagnosed cancer globally and the leading cause of cancer-related death in women.
The National Comprehensive Cancer Network (NCCN) recommends a multigene panel to select an adjuvant systemic chemotherapy, an adjuvant endocrine therapy and monitoring the treatment of metastatic breast cancer. Circulating tumour cells (CTC) in metastatic breast cancer are not yet included in the NCCN guidelines for breast cancer for disease assessment and monitoring, but the persistent increase in CTC after 3 weeks of first-line chemotherapy has poor PFS and OS.
The Altum test comprises a DNA-based multigene panel by NGS in a tumour enriched sample (diagnosis biopsy). After therapy or surgery, this test analyses individual patient cancer-specific alterations in liquid biopsy (circulating free DNA) and CTC in peripheral blood samples. This test of MRD-like measurement assesses treatment response and identifies subsidiary patients who need systematic chemotherapeutic treatment after surgery in breast resection, monitors remission status and detects early relapse.